Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE-100

Shin Nishio, Koji Matsumoto, Kazuhiro Takehara, Naoki Kawamura, Kosei Hasegawa, Nobuhiro Takeshima, Daisuke Aoki, Shoji Kamiura, Atsushi Arakawa, Eiji Kondo, Tomoko Hirakawa, Keiko Yamamoto, Masayuki Aoki, Karen Stein, Stephen Keefe, Keiichi Fujiwara, Kimio Ushijima

研究成果: Article

抜粋

Interim results from the two-cohort, phase 2 KEYNOTE-100 study (NCT02674061) of 376 patients with previously treated advanced recurrent ovarian cancer (ROC) showed that pembrolizumab monotherapy was associated with an objective response rate (ORR) of 8.0% (95% CI, 5.4-11.2). We present outcomes for the Japanese patients (n = 21) enrolled in KEYNOTE-100. Patients with epithelial ROC had received either 1-3 prior chemotherapy lines and had platinum-free interval or treatment-free interval (PFI; TFI) of 3-12 months (cohort A) or 4-6 prior chemotherapy lines and had PFI/TFI of ≥3 months (cohort B). All patients received pembrolizumab 200 mg every 3 weeks as monotherapy for 2 years or until progression, death, unacceptable toxicity or consent withdrawal. Primary objectives were ORR per RECIST v1.1 for each cohort and higher programmed death ligand-1 (PD-L1) tumor expression. The relationship between PD-L1 expression (measured as combined positive score [CPS]) and ORR was assessed. Twenty-one Japanese patients (cohort A, n = 19; cohort B, n = 2) were treated. The median (range) age was 57 (37-78) years; 19 (90.5%) patients had ECOG status of 0 and 16 (76.2%) patients had stage III-IV disease. ORR was 19.0% (95% CI, 5.4-41.9) and seemed to increase with increasing PD-L1 expression. A total of 13 (61.9%) patients had treatment-related adverse events (TRAE), and 5 (23.8%) had grade 3-4 TRAE. There were no treatment-related deaths in this subpopulation. Pembrolizumab monotherapy was associated with antitumor activity in Japanese patients with ROC, with no new safety signals identified in this subpopulation. The data suggested a trend toward higher PD-L1 expression among some patients with higher ORR.

元の言語English
ページ(範囲)1324-1332
ページ数9
ジャーナルCancer science
111
発行部数4
DOI
出版物ステータスPublished - 2020 4 1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

フィンガープリント Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE-100' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Nishio, S., Matsumoto, K., Takehara, K., Kawamura, N., Hasegawa, K., Takeshima, N., Aoki, D., Kamiura, S., Arakawa, A., Kondo, E., Hirakawa, T., Yamamoto, K., Aoki, M., Stein, K., Keefe, S., Fujiwara, K., & Ushijima, K. (2020). Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE-100. Cancer science, 111(4), 1324-1332. https://doi.org/10.1111/cas.14340